Effects of KW-3635, a Specific Thromboxane A2-Receptor Antagonist, on the Development of Lupus Nephritis in NZB × NZW F1 Mice

We examined the effect of KW-3635, a specific thromboxane A2 (TXA2)-receptor antagonist, on the development of lupus nephritis in NZB × NZW F1 mice. KW-3635 was orally given once a day for 33 weeks beginning at eight weeks of age. In the control group, the mice began to die at 39 weeks of age, showi...

Full description

Saved in:
Bibliographic Details
Published in:Japanese journal of pharmacology 1993, Vol.63(4), pp.433-438
Main Authors: Kawakage, Michiyo, Mizumoto, Hideaki, Nukui, Etsuko, Sate, Soichiro, Karasawa, Akira
Format: Article
Language:English
Subjects:
Biological and medical sciences
Kidney
Kidney, Nephritis
KW-3635
Medical sciences
Nephritis
Pharmacology. Drug treatments
Skin, nail, hair, dermoskeleton
Thromboxane A2-receptor antagonist
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We examined the effect of KW-3635, a specific thromboxane A2 (TXA2)-receptor antagonist, on the development of lupus nephritis in NZB × NZW F1 mice. KW-3635 was orally given once a day for 33 weeks beginning at eight weeks of age. In the control group, the mice began to die at 39 weeks of age, showing severe proteinuria and histopathologic abnormality in the renal glomeruli. Administration of KW-3635 (30 mg/kg/day) significantly reduced urinary protein excretion (1.7±0.9 vs. 8.5±2.4 mg/6 hr/mouse, P
ISSN:0021-5198
1347-3506
DOI:10.1254/jjp.63.433